Syed Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Syed Ahmad has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Sudarshan Balla
Department of Cardiology, West Virginia University, Morgantown, Wv, USA
3 shared publications - Brijesh Patel
Department of Internal Medicine, Division of Cardiology, Indiana University, Indianapolis, IN 46202, USA
2 shared publications - HangYu Watson
West Virginia University
2 shared publications - Jonathon Leipsic
Department of Radiology, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada
2 shared publications Maan Awad
Department of Internal Medicine, West Virginia University, 1 Medical Center Dr, Morgantown, WV 26506
2 shared publications- Philippe Pibarot
Université Laval
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 641
Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study
Next-generation Bruton’s tyrosine kinase inhibitors (BTKis) such as acalabrutinib and zanubrutinib have improved treatment outcomes in B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM), while reducing off-target toxicities compared to ibrutinib. However, their comparative cardiovascular safety profiles remain poorly characterized. This study evaluates real-world cardiovascular and clinical outcomes between zanubrutinib and acalabrutinib using a large multi-center database. We conducted a retrospective cohort study using the TriNetX Research Network (October 2017–December 2024) including adult patients with CLL, MCL, WM, or small B-cell lymphoma treated with zanubrutinib or acalabrutinib. Patients with prior exposure to other BTKis were excluded. After 1:1 propensity score matching, 2887 patients were included in each cohort. We assessed one-year outcomes including new-onset atrial fibrillation/flutter, cerebral infarction, hypertension, and all-cause mortality using Cox proportional hazards modeling. The rate of AF/flutter events observed in the zanubrutinib group (4.05%) was numerically lower compared to the acalabrutinib group (5.25%). Time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time (HR 0.777, 95% CI 0.597–1.012; p = 0.06), which was similar in binary analysis (OR 0.761, 95% CI 0.581–0.997; p = 0.05). Cerebral infarction rates were similar between groups (1.09% vs. 1.12%), with no significant difference in time-to-event analysis (HR 0.984, 95% CI 0.596–1.626; p = 0.95) or binary analysis (p = 0.91). There was no significant difference in onset of hypertension in the zanubrutinib cohort (HR 1.199, 95% CI 0.957–1.501; p = 0.11) All-cause mortality was not statistically significant between the two groups (HR 0.865, 95% CI 0.740–1.012; p = 0.07). In this large, real-world analysis, fewer AF/flutter events were observed with zanubrutinib at one year; however, time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time. Notably, hypertension, cerebral infarction, and all-cause mortality occurred at similar rates. This suggests zanubrutinib and acalabrutinib share similar cardiovascular safety profiles overall. However these findings are hypothesis-generating and require prospective validation before definitive conclusions about cardiovascular risk can be drawn.
- 21 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 641
Open AccessComparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study
Next-generation Bruton’s tyrosine kinase inhibitors (BTKis) such as acalabrutinib and zanubrutinib have improved treatment outcomes in B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM), while reducing off-target toxicities compared to ibrutinib. However, their comparative cardiovascular safety profiles remain poorly characterized. This study evaluates real-world cardiovascular and clinical outcomes between zanubrutinib and acalabrutinib using a large multi-center database. We conducted a retrospective cohort study using the TriNetX Research Network (October 2017–December 2024) including adult patients with CLL, MCL, WM, or small B-cell lymphoma treated with zanubrutinib or acalabrutinib. Patients with prior exposure to other BTKis were excluded. After 1:1 propensity score matching, 2887 patients were included in each cohort. We assessed one-year outcomes including new-onset atrial fibrillation/flutter, cerebral infarction, hypertension, and all-cause mortality using Cox proportional hazards modeling. The rate of AF/flutter events observed in the zanubrutinib group (4.05%) was numerically lower compared to the acalabrutinib group (5.25%). Time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time (HR 0.777, 95% CI 0.597–1.012; p = 0.06), which was similar in binary analysis (OR 0.761, 95% CI 0.581–0.997; p = 0.05). Cerebral infarction rates were similar between groups (1.09% vs. 1.12%), with no significant difference in time-to-event analysis (HR 0.984, 95% CI 0.596–1.626; p = 0.95) or binary analysis (p = 0.91). There was no significant difference in onset of hypertension in the zanubrutinib cohort (HR 1.199, 95% CI 0.957–1.501; p = 0.11) All-cause mortality was not statistically significant between the two groups (HR 0.865, 95% CI 0.740–1.012; p = 0.07). In this large, real-world analysis, fewer AF/flutter events were observed with zanubrutinib at one year; however, time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time. Notably, hypertension, cerebral infarction, and all-cause mortality occurred at similar rates. This suggests zanubrutinib and acalabrutinib share similar cardiovascular safety profiles overall. However these findings are hypothesis-generating and require prospective validation before definitive conclusions about cardiovascular risk can be drawn.
- Open Access
- 24 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 574
Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Background/Aim: The addition of an immune-checkpoint inhibitor (ICI) to chemotherapy improves outcomes in both early-stage and metastatic triple-negative breast cancer (TNBC). However, ICIs are associated with immune-related adverse events (irAEs), such as cardiotoxicity, raising concerns for patients receiving both anthracyclines and ICIs. We sought to determine if combining anthracycline and ICI in TNBC is associated with greater cardiotoxicity than anthracycline alone. Methods: A retrospective cohort study was conducted at a large academic center. Two cohorts were analyzed: anthracycline plus ICI and anthracycline alone. Demographics, comorbidities, medications, cardiac imaging, and outcomes were reviewed. Time to adverse cardiac events were compared. Results: A total of 382 patients were included: 297 received anthracyclines without ICI, and 85 received both. There were no major differences in baseline characteristics. The rate of acute cardiac events was 3.4% in the anthracycline-alone cohort and 3.5% in the anthracycline-plus-ICI cohort (p > 0.99) over a median of 1232 days of follow up (median of 1336 days in the anthracycline only group; median of 704 days in the ICI group). No significant differences in acute heart failure, acute coronary syndrome, myocarditis, or pericardial effusion were observed. Kaplan–Meier analysis showed no significant difference in cardiac event-free survival (p = 0.60). Furthermore, there was no significant difference in time to cardiac events between the two groups following competing risk analysis when accounting for both prior coronary artery disease (HR = 1.32, 95% CI: [0.42, 4.14], p = 0.64) and age (HR = 1.64, 95% CI: [0.52, 5.19], p = 0.40). Conclusions: This single-institution analysis did not identify a significant increase in cardiotoxicity with the addition of an ICI to anthracycline therapy in patients with TNBC. Active surveillance for cardiotoxicities should continue in patients receiving ICI in addition to anthracycline therapy.
- 24 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 574
Open AccessCardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Background/Aim: The addition of an immune-checkpoint inhibitor (ICI) to chemotherapy improves outcomes in both early-stage and metastatic triple-negative breast cancer (TNBC). However, ICIs are associated with immune-related adverse events (irAEs), such as cardiotoxicity, raising concerns for patients receiving both anthracyclines and ICIs. We sought to determine if combining anthracycline and ICI in TNBC is associated with greater cardiotoxicity than anthracycline alone. Methods: A retrospective cohort study was conducted at a large academic center. Two cohorts were analyzed: anthracycline plus ICI and anthracycline alone. Demographics, comorbidities, medications, cardiac imaging, and outcomes were reviewed. Time to adverse cardiac events were compared. Results: A total of 382 patients were included: 297 received anthracyclines without ICI, and 85 received both. There were no major differences in baseline characteristics. The rate of acute cardiac events was 3.4% in the anthracycline-alone cohort and 3.5% in the anthracycline-plus-ICI cohort (p > 0.99) over a median of 1232 days of follow up (median of 1336 days in the anthracycline only group; median of 704 days in the ICI group). No significant differences in acute heart failure, acute coronary syndrome, myocarditis, or pericardial effusion were observed. Kaplan–Meier analysis showed no significant difference in cardiac event-free survival (p = 0.60). Furthermore, there was no significant difference in time to cardiac events between the two groups following competing risk analysis when accounting for both prior coronary artery disease (HR = 1.32, 95% CI: [0.42, 4.14], p = 0.64) and age (HR = 1.64, 95% CI: [0.52, 5.19], p = 0.40). Conclusions: This single-institution analysis did not identify a significant increase in cardiotoxicity with the addition of an ICI to anthracycline therapy in patients with TNBC. Active surveillance for cardiotoxicities should continue in patients receiving ICI in addition to anthracycline therapy.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (6) , e250071
Comparison of Diagnostic Parameters Using Cardiac CT–derived Aortic Valve Area and Aortic Valve Calcium Scores for Low-Gradient Aortic Stenosis
In low-gradient aortic stenosis, diagnostic strategies combining cardiac CT–derived aortic valve area with aortic valve calcium (AVC) or AVC density scores showed comparable diagnostic performance to baseline models of AVC alone or AVC with aortic valve area from echocardiography.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (6) , e250071
Comparison of Diagnostic Parameters Using Cardiac CT–derived Aortic Valve Area and Aortic Valve Calcium Scores for Low-Gradient Aortic Stenosis
In low-gradient aortic stenosis, diagnostic strategies combining cardiac CT–derived aortic valve area with aortic valve calcium (AVC) or AVC density scores showed comparable diagnostic performance to baseline models of AVC alone or AVC with aortic valve area from echocardiography.
- Open Access
Takotsubo Cardiomyopathy Triggered by Electrical Cardioversion and Complicated by Ventricular Septal Rupture
- Open Access
Risk Stratification of Patients With Moderate Aortic Stenosis Using Aortic Valve Calcium
Objectives: To evaluate whether aortic valve calcium (AVC) scoring by cardiac CT can enhance risk stratification and identify high-risk patients among those with moderate aortic stenosis (AS). Background: Moderate AS is traditionally considered benign, yet emerging evidence suggests a subset may experience adverse outcomes similar to those with severe AS. AVC scoring has been validated for diagnosing severe AS but its prognostic value in moderate AS remains unclear. Methods: A retrospective cohort study of 606 patients with moderate aortic stenosis (MAS) for whom aortic valve calcium (AVC) assessment was recommended on echocardiogram reports. Patients were categorized into two groups: those who underwent AVC (n=159) and those who did not (n=447). Primary outcomes included aortic valve replacement (AVR) and all-cause mortality. Secondary outcomes included time to severe AS diagnosis and time to AVR. Results: A significantly higher proportion of patients in the CT cohort reached a diagnosis of severe AS (28.8% vs. 19.9%, p=0.037) and underwent valve intervention (32.6% vs. 14.1%, p1200 AU) were more likely to undergo valve intervention compared with non-severe AVC (HR 2.60, 95% CI 1.42-4.74, p=0.002). Patients in the CT cohort were more likely to undergo valve intervention (HR 3.17, CI 2.04-4.91, p<0.001), and had a significantly lower all-cause mortality (HR 0.32, CI 0.16-0.61, p=0.001) compared to the no-CT cohort. Conclusion: A practice algorithm incorporating AVC for risk stratification of MAS patients can lead to better outcomes. Role of AVC based decision-making in patients with MAS needs further study in a randomized trial.
Open AccessRisk Stratification of Patients With Moderate Aortic Stenosis Using Aortic Valve Calcium
Objectives: To evaluate whether aortic valve calcium (AVC) scoring by cardiac CT can enhance risk stratification and identify high-risk patients among those with moderate aortic stenosis (AS). Background: Moderate AS is traditionally considered benign, yet emerging evidence suggests a subset may experience adverse outcomes similar to those with severe AS. AVC scoring has been validated for diagnosing severe AS but its prognostic value in moderate AS remains unclear. Methods: A retrospective cohort study of 606 patients with moderate aortic stenosis (MAS) for whom aortic valve calcium (AVC) assessment was recommended on echocardiogram reports. Patients were categorized into two groups: those who underwent AVC (n=159) and those who did not (n=447). Primary outcomes included aortic valve replacement (AVR) and all-cause mortality. Secondary outcomes included time to severe AS diagnosis and time to AVR. Results: A significantly higher proportion of patients in the CT cohort reached a diagnosis of severe AS (28.8% vs. 19.9%, p=0.037) and underwent valve intervention (32.6% vs. 14.1%, p1200 AU) were more likely to undergo valve intervention compared with non-severe AVC (HR 2.60, 95% CI 1.42-4.74, p=0.002). Patients in the CT cohort were more likely to undergo valve intervention (HR 3.17, CI 2.04-4.91, p<0.001), and had a significantly lower all-cause mortality (HR 0.32, CI 0.16-0.61, p=0.001) compared to the no-CT cohort. Conclusion: A practice algorithm incorporating AVC for risk stratification of MAS patients can lead to better outcomes. Role of AVC based decision-making in patients with MAS needs further study in a randomized trial.
- 11 June 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 50, 102267
The prevalence and prognostic impact of additive abnormal stress exercise markers in patients with normal stress myocardial perfusion imaging
- 11 June 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 50, 102267
The prevalence and prognostic impact of additive abnormal stress exercise markers in patients with normal stress myocardial perfusion imaging